GlassScriptPhysician profile
Kevin Verde
NPI 1801344692
$3,914.95
in general payments reported to CMS, 2019-2025
27 companies · $793 in 2025
The $793 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,507 · 2022: $815 · 2023: $223 · 2024: $577 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,592.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,085.65 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $550.67 | 2021-2025 | Evenity, Repatha, Repatha |
| Novo Nordisk INC | $424.77 | 2021-2025 | Wegovy |
| Pfizer INC. | $197.34 | 2021-2024 | |
| Abbvie INC. | $184.58 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $166.84 | 2021-2022 | |
| Exact Sciences Corporation | $159.75 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.77 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Sanofi-Aventis U.S. LLC | $117.72 | 2021-2022 | |
| Biogen, INC. | $114.68 | 2021-2022 | |
| Amarin Pharma, INC. | $112.67 | 2021-2022 | |
| Lilly USA, LLC | $109.54 | 2021-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $78.51 | 2022-2025 | Proclaim, Freestyle Libre |
| Almatica Pharma LLC | $70.68 | 2021-2022 | |
| Glaxosmithkline, LLC. | $63.24 | 2021-2024 | Arexvy, Shingrix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $48.54 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $43.29 | 2021 | |
| Dexcom, INC. | $42.26 | 2024 | Dexcom G6 Transmitter |
| Coloplast Corp | $40.03 | 2024 | |
| Gilead Sciences, INC. | $31.97 | 2025 | |
| Novartis Pharmaceuticals Corporation | $26.43 | 2021 | |
| Acerus Pharmaceuticals Corporation | $25.47 | 2022 | |
| Astellas Pharma US INC | $20.21 | 2022 | |
| Hologic Sales and Service, LLC | $19.77 | 2023 | Affirm Prone Biopsy System |
| Genentech USA, INC. | $16.98 | 2021 | |
| Ibsa Pharma INC. | $13.34 | 2024 | Licart, Tirosint |
| Radius Health, INC. | $13.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Verde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.